Download as PDF
Federal Register / Vol. 83, No. 30 / Tuesday, February 13, 2018 / Notices
the Director, Management Analysis and
Services Office, CDC, pursuant to Public
Law 92–463. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease, Disability,
and Injury Prevention and Control Special
Emphasis Panel (SEP); Funding Opportunity
Announcement (FOA), IP18–001, Reducing
Disparities in Vaccination Coverage by
Poverty Status Among Young Children and
IP18–003, Understanding and Addressing the
Disparity in Vaccination Coverage Among
U.S. Adolescents Living in Rural versus
Urban Areas.
Dates: March 20, 2018 and March 21, 2018.
Time: 10:00 a.m.–5:00 p.m. (EDT)
Place: Teleconference, Centers for Disease
Control and Prevention, Room 1080, 8
Corporate, Atlanta, GA 30329.
Agenda: To review and evaluate grant
applications.
For Further Information Contact: Gregory
Anderson, M.S., M.P.H., Scientific Review
Officer, CDC, 1600 Clifton Road NE, Mailstop
E–60, Atlanta, Georgia 30333, (404) 718–
8833, gca5@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register Notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2018–02826 Filed 2–12–18; 8:45 am]
BILLING CODE 4163–18–P
Exposure and Prevention Advisory
Committee shall, at a minimum: (1)
Review the Federal programs and
services available to individuals and
communities exposed to lead; (2) review
current research on lead exposure to
identify additional research needs; (3)
review and identify best practices, or
the need for best practices regarding
lead screening and the prevention of
lead poisoning; (4) identify effective
services, including services relating to
healthcare, education, and nutrition for
individuals and communities affected
by lead exposure and lead poisoning,
including in consultation with, as
appropriate, the lead exposure registry
as established in Section 2203(b) of
Public Law 114–322; and (5) undertake
any other review or activities that the
Secretary determines to be appropriate.
This advisory committee will review
research and Federal programs and
services related to lead poisoning and to
identify effective services and best
practices for addressing and preventing
lead exposures in communities.
FOR FURTHER INFORMATION CONTACT:
Perri Ruckart, M.P.H., Epidemiologist,
CDC, 4770 Buford Highway NE, Atlanta,
Georgia 30341, telephone (770) 488–
3808; afp4@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2018–02823 Filed 2–12–18; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Lead Exposure and Prevention
Advisory Committee (LEPAC); Notice
of Establishment
Centers for Disease Control and
Prevention
ACTION:
Notice of charter establishment.
Pursuant to the Section 2203
of Public Law 114–322 (Water
Infrastructure Improvements for the
Nation Act)(Registry for Lead Exposure
and Advisory Committee), and the
Federal Advisory Committee Act of
October 6, 1972, the Director, Centers
for Disease Control and Prevention
(CDC), announces the establishment of
the Lead Exposure and Prevention
Advisory Committee. The Lead
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
23:12 Feb 12, 2018
Jkt 244001
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Management Analysis and
Services Office, CDC, pursuant to Public
Law 92–463. The grant applications and
PO 00000
Frm 00019
Fmt 4703
Sfmt 4703
6177
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease, Disability,
and Injury Prevention and Control Special
Emphasis Panel; (SEP) DP18–001, Etiology
and Outcome of Inflammatory Bowel Disease.
Date: April 11, 2018.
Time: 11:00 a.m.–6:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact: Jaya
Raman Ph.D., Scientific Review Officer, CDC,
4770 Buford Highway, Mailstop F80, Atlanta,
Georgia 30341, Telephone: (770) 488–6511,
kva5@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2018–02829 Filed 2–12–18; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Management Analysis and
Services Office, CDC, pursuant to Public
Law 92–463. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease, Disability,
and Injury Prevention and Control Special
Emphasis Panel (SEP); DD18–001, Birth
Defects Study To Evaluate Pregnancy
exposureS (BD–STEPS) II.
E:\FR\FM\13FEN1.SGM
13FEN1

Agencies

[Federal Register Volume 83, Number 30 (Tuesday, February 13, 2018)]
[Notices]
[Page 6177]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-02823]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Lead Exposure and Prevention Advisory Committee (LEPAC); Notice
of Establishment
ACTION: Notice of charter establishment.
-----------------------------------------------------------------------
SUMMARY: Pursuant to the Section 2203 of Public Law 114-322 (Water
Infrastructure Improvements for the Nation Act)(Registry for Lead
Exposure and Advisory Committee), and the Federal Advisory Committee
Act of October 6, 1972, the Director, Centers for Disease Control and
Prevention (CDC), announces the establishment of the Lead Exposure and
Prevention Advisory Committee. The Lead Exposure and Prevention
Advisory Committee shall, at a minimum: (1) Review the Federal programs
and services available to individuals and communities exposed to lead;
(2) review current research on lead exposure to identify additional
research needs; (3) review and identify best practices, or the need for
best practices regarding lead screening and the prevention of lead
poisoning; (4) identify effective services, including services relating
to healthcare, education, and nutrition for individuals and communities
affected by lead exposure and lead poisoning, including in consultation
with, as appropriate, the lead exposure registry as established in
Section 2203(b) of Public Law 114-322; and (5) undertake any other
review or activities that the Secretary determines to be appropriate.
This advisory committee will review research and Federal programs and
services related to lead poisoning and to identify effective services
and best practices for addressing and preventing lead exposures in
communities.
FOR FURTHER INFORMATION CONTACT: Perri Ruckart, M.P.H., Epidemiologist,
CDC, 4770 Buford Highway NE, Atlanta, Georgia 30341, telephone (770)
488-3808; [email protected].
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2018-02823 Filed 2-12-18; 8:45 am]
BILLING CODE 4163-18-P